Title: WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
Authors: Fosså, A.; Ozcan, M.; Song, Y.; Lee, S. T.; Mensah, F.; Modi, D.; Kim, W. S.; Paszkiewicz‐Kozik, E.; Sawalha, Y.; Sevindik, O. G.; Norasetthada, L.; Santoro, A.; Pathiraja, K.; Chakraborty, S.; Marinello, P.; Lavie, D.
Abstract: B Introduction: b Patients (pts) with I R i / I R i DLBCL who are not candidates for autologous stem cell transplant (ASCT) or CAR T-cell therapy have limited treatment options. Pts must have received >=2 prior lines of therapy, including an alkylating agent, an anthracycline, and an anti-CD20 antibody, and must have been ineligible for or had disease progression after ASCT and CAR T-cell therapy. The ROR1-targeting antibody-drug conjugate zilovertamab vedotin (ZV) had promising antitumor activity and manageable safety in pts with I R i / I R i DLBCL in the phase 1 waveLINE-001 study.
Subjects: DIFFUSE large B-cell lymphomas; TUMOR lysis syndrome; CARCINOEMBRYONIC antigen
Publication: Hematological Oncology, 2023, Vol 41, p208
ISSN: 0278-0232
Publication type: Academic Journal
DOI: 10.1002/hon.3163_136

WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).

Fosså, A.; Ozcan, M.; Song, Y.; Lee, S. T.; Mensah, F.; Modi, D.; Kim, W. S.; Paszkiewicz‐Kozik, E.; Sawalha, Y.; Sevindik, O. G.; Norasetthada, L.; Santoro, A.; Pathiraja, K.; Chakraborty, S.; Marinello, P.; Lavie, D.